Daxor Corporation CEO and President Michael Feldschuh Provides Corporate Update in Letter to Shareholders

Core Insights - Daxor Corporation is focused on advancing healthcare through blood volume measurement technology, aiming to improve patient outcomes and reduce costs for healthcare systems [2][13] - The company reported significant growth in revenue and customer acquisition, with a 116.5% year-on-year revenue increase for 2024 and over 100% growth in the first two months of 2025 [4][5] - Daxor's next-generation blood volume analyzer is under FDA review and is expected to enhance the speed and accuracy of fluid management in clinical settings [6][7][8] Financial Performance - As of December 31, 2024, Daxor's net assets increased to $36.79 million, up from $34.01 million in 2023, primarily due to the appreciation of the operating division [3] - The operating division achieved cash-flow break-even in Q1 2025, excluding stock-based compensation and other non-cash expenses [4] - The company reported net dividend income of $104,115 and net realized gains of $1.36 million for the year ended December 31, 2024 [3] Product Development and Innovation - Daxor's next-generation blood volume analyzer is validated to provide results in as little as 15 minutes, significantly improving the speed of diagnosis [7] - The company plans to acquire exclusive rights to manufacture additional diagnostic products, which are expected to be cash flow positive and enhance profit margins [9] - Ongoing research and clinical studies have demonstrated the effectiveness of Daxor's blood volume analysis in various medical conditions, including heart failure [12] Strategic Partnerships and Contracts - Daxor has secured contracts with the Department of Defense and received NIH grants totaling over $350,000, supporting its research and development efforts [11] - The company has signed multiple new accounts and is expanding its customer base through strategic agreements and product offerings [4][11] Market Position and Future Outlook - Daxor is positioned as a leader in blood volume measurement technology, with a focus on non-invasive and accurate diagnostic solutions [16] - The company anticipates significant interest in its next-generation systems upon FDA approval, which will likely drive further adoption in both hospital and outpatient settings [8] - Daxor aims to enhance its operational designation and increase its market presence by leveraging its growing product portfolio and clinical evidence [14]